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INTRODUCTION
Intravenous immunoglobulin (IVIG) is an established
replacement therapy for primary immunodeficiency (1).
However, the mechanism of immunoregulatory action is
poorly understood, even though it is used as an immuno-
modulatory treatment for many immune-mediated diseases
including Kawasaki disease, and immune thrombocytopenic
purpura (ITP) (2, 3). Several studies have presented evidence
for IVIG as a modulater of cell mediated immune responses
both in vivo and in vitro. IVIG prolongs the Fc receptor-
mediated clearance of IgG coated cells and decreases anti-
body-dependent cytotoxicity (3-5). It also solubilizes formed
tissue immune complexes and inhibits autoantibody pro-
duction (6, 7). Furthermore it inhibits the production of cer-
tain cytokines (8, 9), decreases T-cell dependent polyclonal
immunoglobulin production by B cells (10-12) and neutral-
izes pathogenic antibodies or toxins (13, 14). 
Research into the effects of IVIG have shown that in a
dose-dependent fashion, it can inhibit lymphocyte prolifera-
tion in vitro to phytohemagglutinin (PHA) (15-17), con-
canavalin A, pokeweed mitogen, and Staphylococcus aureus
protein A (17), phorbol myristate acetate (PMA) with iono-
mycin (18), anti-CD3 monoclonal antibody (MAb) (9, 18)
and in the mixed lymphocyte reaction (16, 17). However,
low concentrations of IVIG which are enough to suppress
the production of immunoglobulins by B cells do not effect
T cell proliferation (19).
In this study, the in vitro effects of IVIG on PBMC acti-
vation and proliferation using different T-cell stimulants
have been analyzed. PBMCs were activated in an antigen
nonspecific cell surface receptor-mediated manner using
PHA or anti-CD3 MAb, and in a direct activation manner
that bypasses the cell surface receptor using PMA, and in an
antigen-specific manner using purified protein derivatives
of Mycobacterium (PPD). The main focus of this investigation
was the effects of IVIG concentration on cellular proliferation
in vitro. The data provides evidence that in limited IVIG
concentrations in vitro, there may be various mechanisms
responsible for modulating PBMCs. 
MATERIALS AND METHODS 
Cell preparation
Human PBMCs were isolated from healthy donors who
tested positive for Mantoux by Ficoll-Hypaque gradient
centrifugation (Phamacia Biotech, Uppsala, Sweden). The
cells were used immediately after isolation. Freeze-dried
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Varying Effects of Intravenous Immunoglobulin on Mononuclear Cell 
Proliferation In Vitro
Intravenous immunoglobulin (IVIG) is being increasingly used to treat numerous
immune-mediated diseases. However, there is a paucity of knowledge on the
specific mode of action of IVIG in vivo. In this study, the in vitro effects of IVIG
on peripheral blood mononuclear cell (PBMC) proliferation using phytohemag-
glutinin (PHA), anti-CD3 monoclonal antibody (MAb), phorbol myristate acetate
(PMA), or purified protein derivatives (PPD) have been analyzed. The PBMCs
were obtained from more than 10 individual donors. In all cases, IVIG almost
completely inhibited PBMC proliferation at concentration above 20 mg/mL except
when used in conjunction with PMA. PHA-induced proliferation of PBMCs at
concentrations ranging from 1 to 15 mg/mL did not show significant differences.
Anti-CD3 MAb-induced proliferation showed dose-dependent inhibition at con-
centrations ranging from 1 to 10 mg/mL. Interestingly, PMA-induced proliferation
of PBMCs showed a dose-dependent increase at the same concentration range.
PPD-induced proliferation of PBMC at concentrations ranging from 1 to 10 mg/mL
did not show any statistically significant differences. These results suggest that
high dose IVIG may be necessary to immune modulation in vivo and IVIG has
various effects on PBMCs proliferation in limited concentration in vitro.
Key Words : Immunoglobulins, Intravenous; Proliferating Cell ; Nuclear AntigenIVIG for clinical use, derived from a large pool of donor
plasma (>10,000), was obtained from the Green Cross Co.
(IV globulin, Korea). The final concentrations of PHA
(Sigma, St. Louis, U.S.A.), anti-CD3 MAb (Sigma, St. Louis,
U.S.A.), PMA (Sigma, St. Louis, U.S.A.) and PPD (lysate of
H37Rv strain, gift from Dr. Paik, Dept. of Microbiology,
Chungnam National University, Korea) used were 6.25  g/
mL, 50 ng/mL, 100 ng/mL, and 2.5  g/mL, respectively.
The IVIG for clinical use was dissolved in culture medium,
and human albumin (20%, Green Cross Co. Korea) and
glucose (50%, JoongWae Co, Korea) were used as controls.
Cell cultures
PBMCs were incubated in 96-well flat bottom tissue cul-
ture plates at 1×105 cells and 200  L per well. The culture
medium consisted of RPMI 1640 (Gibco, Grand Island, NY,
U.S.A.) with L-glutamine (2 mM), penicillin (100 U/mL),
streptomycin (100  g/mL), 2-mercaptoethanol (5 mM),
HEPES buffer (15 mM), sodium bicarbonate (1 mM), and fetal
bovine serum (10%). The following mitogens added to the
plates: PHA (6.5  g/mL), anti-CD3 MAb (50 ng/mL), PMA
(100 ng/mL), or PPD (2.5  g/mL) with graded concentra-
tions of IVIG (0-50 mg/mL). The final volume of each well
was adjusted to 250  L with the culture media. Culture
plates were kept in a humidified, 37℃ incubator with 5%
CO2 for 4 days. After 3 days, 1  Ci 3H-thymidine was added
and the cells were harvested 20 hr later. 3H-thymidine incor-
poration was measured with a Packard beta-counter (Matrix
9600, Meriden, CT, U.S.A.). Experimental counts (cpm) were
calculated by subtracting the average back ground from the
mean of duplicate experimental values. Cell viability, asses-
sed by trypan blue staining, was unaffected by IVIG sup-
plementation in any of the cultures.
Statistical methods 
The data was presented using the mean and standard de-
viations. The ratio of proliferation was calculated within
individual experiments. The ratio from the control value
(without IVIG) was set to 1.0 and compared to the experi-
mental results. The differences were computed for their sta-
tistical significance using the t-test for paired data within
the range of IVIG concentrations 0 mg/mL to 30 mg/mL.
A p<0.05 was considered statistically significant (SPSS ver-
sion 8.0). 
RESULTS
From around 10 individual donors, nearly complete inhi-
bition of various stimuli-induced PBMC proliferation except
PMA was observed at IVIG concentration above 20 mg/mL.
At a final IVIG concentration of 30 mg/mL or more almost
100% inhibition was observed in all experiments. In these
experiments, the background cpm (without stimulants) was
<30. In each experiment, the mean cpm of the graded IVIG
concentrations was calculated with the mean cpm without
IVIG (0 mg/mL) set at 1.0. The proliferation ratio is the ratio
between the mean cpm (0 mg/mL IVIG) and the graded
IVIG concentrations. In control study, various concentrations
ranging 1-30 mg/mL of albumin did not show any inhibi-
tions irrespective of stimulants, however, glucose showed
dose-dependent inhibition at the same range of concentra-
tion in all stimulants (Fig. 1) Glucose concentration above
20 mg/dL showed almost complete inhibition.
PHA-induced proliferation of PBMC at concentrations
ranging from 1 to 15 mg/mL did not show any statistically
significant differences. The mean cpm without IVIG (0 mg/
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Fig. 1. Influences of albumin and glucose as controls on peripheral mononuclear cell proliferation induced by various stimulants. Albu-
min (n=6) did not affect on cell proliferation, but glucose (n=6) inhibited cell proliferation in dose-dependent fashion. Proliferation ratio
means the ratio between cpm of 0 mg/mL of albumin or glucose and that of graded concentrations of albumin or glucose (ranging from
1 mg/mL to 20-30 mg/mL).
Albumin A Glucose BmL) was 7,142±2,723 (Fig. 2A). Anti-CD3 MAb-induced
proliferation at concentrations ranging from 1 to 10 mg/mL
showed dose-dependent inhibition (Fig. 2B). Anti-CD3 MAb
induced proliferation was inhibited quite efficiently by IVIG,
and at 5 mg/mL the proliferation ratio was 0.34. However,
interestingly PMA-induced the proliferation of PBMC at
concentrations ranging from 1 to 10 mg/mL showed dose-
dependent increase. PMA induced the active proliferation of
PMNCs, and the proliferation ratios at concentrations of 5,
10, 15 and 20 mg/mL were 2.7±1.0, 5.2±1.9, 2.8±1.3,
and 0.9±0.6, respectively (Fig. 2C). PPD-induced prolifer-
ation of PBMC showed a dose-dependent pattern, however
at concentrations ranging from 1 to 10 mg/mL did not show
any statistical differences (Fig. 2D).
DISCUSSION
In this investigation, it was found that in all stimulants,
IVIG (>20 mg/mL) have an inhibitory effect on PBMC pro-
liferation, as measured by 3H-thymidine. High-dose induced
inhibition was observed regardless of how the cell was acti-
vated, i.e., by antigen specific stimulation (PPD) for sensi-
tized T cell, via T-cell receptor (anti-CD3 MAb), via antigen-
nonspecific lectin stimulation (PHA), or direct stimulation
without receptors (PMA). 
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Fig. 2. Effects of IVIG on peripheral blood mononuclear cell proliferation induced by various stimulants. Nearly complete inhibition
except PMA by IVIG at concentration above 20 mg/mL was observed. At a final concentration of 30 mg/mL or more of IVIG, almost
100% inhibition was observed in all experiments. (A) PHA (6.25  g/mL)-stimulated proliferations (n=12) of ranging from 1 mg/mL to 15
mg/mLof IVIG were not statistically significant. Mean cpm without IVIG (0 mg/mL) was 7,142±2,713 and set 1.0. (B) In anti-CD3 mono-
clonal antibody (50 ng/mL) stimulaton (n=10), proliferation ratios of ranging from 1 mg/mL to 10 mg/mL of IVIG show significant dose
dependent decrease (mean cpm without IVIG was 3,261±1.664). (C) Proliferation ratios of PMA (10 ng/mL, n=10) show significant
dose-dependent increase of ranging from 1 mg/mL to 10 mg/mL (mean cpm without IVIG, 1,351±422). (D) PPD-stimulated prolifera-
tions (2.5  g/mL, n=8) show no significant inhibition between from 1 mg/mL to 10 mg/mL of IVIG concentration (mean cpm without
IVIG, 272±219). In all experiments, background cpm (without stimulant) was below 30. 
Abbreviations; n, numbers of materials; PHA, phytohemagglutinin; anti-CD3, anti-CD3 monoclonal antibody; PMA, phobol myristate
acetate; PPD, purified protein derivatives.
A Anti-CD3 B
PMA C PPD DHowever, at IVIG concentrations ranging from 1 mg/mL
to 10 or 15 mg/mL, PHA- and PPD-induced proliferation
showed no significant differences (Fig. 2A, D). Anti-CD3
MAb-induced proliferation was inhibited in a dose-depen-
dent manner at concentrations between 1 mg/mL and 10
mg/mL (Fig. 2B). However, PMA-induced proliferation
showed dose-dependent increases at the same range. These
results suggest that IVIG has varying effects on cell activa-
tion and proliferation in vitro and modulates cell prolifera-
tion in limited concentrations in vitro. 
Other studies have shown that high IVIG concentrations
inhibit lymphocyte proliferation in the presence of various
stimulants irrespective of the cell types including several
malignant cell lines (16), and of the IVIG preparations (whole
IgG, F(ab′ )2fragment (17, 20), Fc fragments (15, 20), or repu-
rified IVIG (17), IgG from single or five donors (17)). 
IVIG have shown diverse immunoregulatory actions.
However, the inhibitory mechanism of cell proliferation is
at present unknown. High-dose IVIG seems not to induce
cell death (15-20), but arrests the cell cycle in G0/G1 stage
(16). It is suggested that IVIG interacts with a number of
surface antigens of T cells including the T-cell receptor (16,
17), the Fc receptor (15) and modulates IL-2 (18, 20). Recent-
ly it is reported that high dose IVIG induced apoptosis in
vitro in leukemic cell lines and in CD40-activated normal
tonsillar B cells via Fas apoptotic pathway (21). However,
the role of anti-Fas antibodies in IVIG on apoptosis is con-
troversial (22). 
It is suggested that materials containing IVIG as stabilizers
(glucose, albumin, sucrose, maltose, etc), different culture
conditions or IVIG preparations used in the experiments
may lead to varying results (17, 23). The preparation used
in this study contains glucose (5%) and albumin (20%) as
stabilizer. We used commercially available human serum
albumin (HAS, 20%) and glucose (50%) as controls. HSA
and glucose, at concentrations corresponding to the dose
present in IVIG preparation (0.2-4.0 mg/mL and 0.08-1.0
mg/mL, respectively) and high-dose HAS (5-30 mg/mL),
had no significant effect on PBMC proliferation that was
induced by any of the stimulants. On the other hand, high-
dose glucose inhibits PBMC proliferation in dose-dependent
fashion (Fig. 1).
Therefore one possible explanation can be proposed that
high doses of IVIG may affect the experimental culture en-
vironment regardless of any type of stimuli like a glucose in
control study, however, varying effects of IVIG in limited
concentrations can rule out this possibility.
Although several studies have shown that low IVIG doses
(below 10 mg/mL) can inhibit lymphocyte proliferation,
inhibition of proliferation induced by various stimuli at
higher IVIG concentration in vitro may be inferred that
immune modulation of IVIG in vivo requires a high con-
centration. 
It has been suggested that IVIG concentrations in vitro
ranging from 20 mg/mL to 40 mg/mL may correspond to
serum levels observed when IVIG is given in clinical doses
(15, 16, 21). In our clinical study of twelve children with
Kawasaki disease, it was found that after administration of
IVIG of 2 g/kg for 12 hr, the serum IgG levels showed a
concentration of 3,091±270 mg/dL (30.9 mg/mL) after 2
hr, 2,723±259 mg/dL after 24 hr, 2,470±311 mg/dL
after 7 days, and 908±218 mg/dL before IVIG infusion,
respectively. This finding show that a high IVIG dose can
maintain the serum level of IgG above 20 mg/mL for longer
than 7 days. Thus, although the inhibitory effects of IVIG
in vitro requires supraphysiologic levels (>20 mg/mL) of
IgG, this range of level may be easily reached in vivo by
using standard treatment schemes with a IVIG of high dose
for autoimmune disease. If the inhibition of proliferation to
various stimulants inferred from immune modulatory effect
of IVIG, IVIG concentrations above 20 mg/mL are necessary
to work and maintain an immune modulation in vivo. In
Kawasaki disease or ITP, a high single dose of IVIG (2.0 g/kg)
or divided low doses of IVIG (500 mg/kg/day for 4 days)
did not have any apparent therapeutic results (24). This
finding suggests that a higher serum concentration of IVIG
is required in order to obtain the immunoregulatory effects
regardless of therapeutic schemes. Also we found that high-
dose IVIG treatment in patients with Kawasaki disease in-
duced the changes of the various protein and lipid profiles
including albumin and apolipoprotein A-I within two hours
after IVIG infusion. These findings make us to propose a
hypothesis that immunoregulatory action of IVIG results
from the changes on systemic protein metabolism or the
acceleration of protein catabolism (unpublished observation).
The results of our in vitro study can partly explain the hypoth-
esis derived from our in vivo observation. If IVIG modulate
proteins in vitro system in dose-dependent fashion, IVIG
inhibit the cell proliferation induced by stimulants which
are derived from proteins (anti-CD3, PPD, and PHA) more
effectively than by phobol ester (PMA). In case of PHA, mi-
togenic activity of PHA may have a wide range of its con-
centration to induce peak proliferation. Furthermore, high
concentrations of IVIG may affect the proteins which are
essential to cell proliferation including cytokines synthe-
sized from the cells with stimulants.
Our data showed that IVIG in a limited concentration
(1-15 mg/mL, maybe within physiologic level) has varying
effects on PBMCs in conjunction with other stimuli. Al-
though most of studies have reported that IVIG inhibits
cell proliferation in a dose-dependent fashion, some similar
findings to our results could be found; repurified IVIG via
DEAE-Sephadex adsorption did not inhibit PBMC prolifer-
ation to PHA at a concentration of 15 mg/mL (23), the pro-
liferative response to PMA/ionomycin was not inhibited
over concentrations ranging from 1 to 10 mg/mL (9).
To what extent the various effects that IVIG has on cell
proliferation contribute to the clinically beneficial effect that
Effects of Intravenous Immunoglobulin on Mononuclear Cell 547is observed in many autoimmune diseases, is not known.
However, it is possible that several immunoregulatory effects
of IVIG on immune cells affect patients in different immu-
nologic disease states.
In conclusion, our results suggest that IVIG in higher
concentrations inhibits and IVIG in limited concentrations
modulates the response of PBMCs to various stimuli in vitro.
Further investigation is needed in order to clarify whether
these mechanisms also work in vivo.
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